{"DataElement":{"publicId":"6741257","version":"1","preferredName":"Cutaneous T-cell Lymphoma Response in Blood Category","preferredDefinition":"Response category that describes the disease involvement in blood based on staging and classification criteria for cutaneous T-cell lymphoma (CTCL).","longName":"CTCL_BLOOD_SCR_CAT","context":"CCR","contextVersion":"1","DataElementConcept":{"publicId":"6741249","version":"1","preferredName":"Primary Cutaneous T-Cell Non-Hodgkin Lymphoma Global Response in Blood","preferredDefinition":"A T-cell non-Hodgkin lymphoma arising from the skin. Representative examples include mycosis fungoides and primary cutaneous anaplastic large cell lymphoma._Criteria for the response to treatment in blood, as a component of global response.","longName":"6741233v1.0:6741247v1.0","context":"CCR","contextVersion":"1","ObjectClass":{"publicId":"6741233","version":"1","preferredName":"Primary Cutaneous T-Cell Non-Hodgkin Lymphoma","preferredDefinition":"A T-cell non-Hodgkin lymphoma arising from the skin. Representative examples include mycosis fungoides and primary cutaneous anaplastic large cell lymphoma.","longName":"C3467","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Primary Cutaneous T-Cell Non-Hodgkin Lymphoma","conceptCode":"C3467","definition":"A T-cell non-Hodgkin lymphoma arising from the skin. Representative examples include mycosis fungoides and primary cutaneous anaplastic large cell lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"883A32B7-C39E-1131-E053-F662850AA707","latestVersionIndicator":"Yes","beginDate":"2019-05-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-05-06","modifiedBy":"ONEDATA","dateModified":"2019-05-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"6741247","version":"1","preferredName":"Global Response in Blood","preferredDefinition":"Criteria for the response to treatment in blood, as a component of global response.","longName":"C159969","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Global Response in Blood","conceptCode":"C159969","definition":"Criteria for the response to treatment in blood, as a component of global response.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"88391626-9BF2-31C1-E053-F662850A37E4","latestVersionIndicator":"Yes","beginDate":"2019-05-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-05-06","modifiedBy":"ONEDATA","dateModified":"2019-05-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CCR:Center for Cancer Research","workflowStatus":"RELEASED","registrationStatus":"Application","id":"88391626-9C03-31C1-E053-F662850A37E4","latestVersionIndicator":"Yes","beginDate":"2019-05-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-05-06","modifiedBy":"COOPERM","dateModified":"2019-05-07","changeDescription":"Created for NCI-INC0370865: 19C0076 qns curation request. 4.17.19 mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6741227","version":"1","preferredName":"Global Response in Blood Category","preferredDefinition":"Criteria for the response to treatment in blood, as a component of global response._A grouping of items based on some commonality or by user defined characteristics.","longName":"GR_BLD_CAT","context":"CCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"10","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"CR","valueDescription":"Global Complete Response in Blood","ValueMeaning":{"publicId":"6741228","version":"1","preferredName":"Global Complete Response in Blood","longName":"6741228","preferredDefinition":"A score of B0 by repeat bone marrow biopsy with no residual disease.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Global Complete Response in Blood","conceptCode":"C159970","definition":"A score of B0 by repeat bone marrow biopsy with no residual disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"883A28B7-452B-21A5-E053-F662850ACC0A","latestVersionIndicator":"Yes","beginDate":"2019-05-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-05-06","modifiedBy":"ONEDATA","dateModified":"2019-05-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"883A28B7-4544-21A5-E053-F662850ACC0A","beginDate":"2019-05-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-05-06","modifiedBy":"ONEDATA","dateModified":"2019-05-06","deletedIndicator":"No"},{"value":"PD","valueDescription":"Global Progressive Disease in Blood","ValueMeaning":{"publicId":"6741229","version":"1","preferredName":"Global Progressive Disease in Blood","longName":"6741229","preferredDefinition":"A change from B0 to B2; or greater than 50 percent increase from baseline and at least 5,000 neoplastic cells per microliter; or loss of response: in those with partial response who were originally B2 at baseline, greater than 50 percent increase from nadir and at least 5,000 neoplastic cells per microliter.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Global Progressive Disease in Blood","conceptCode":"C159975","definition":"A change from B0 to B2; or greater than 50 percent increase from baseline and at least 5,000 neoplastic cells per microliter; or loss of response: in those with partial response who were originally B2 at baseline, greater than 50 percent increase from nadir and at least 5,000 neoplastic cells per microliter.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"883A28B7-4550-21A5-E053-F662850ACC0A","latestVersionIndicator":"Yes","beginDate":"2019-05-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-05-06","modifiedBy":"ONEDATA","dateModified":"2019-05-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"883A28B7-4569-21A5-E053-F662850ACC0A","beginDate":"2019-05-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-05-06","modifiedBy":"ONEDATA","dateModified":"2019-05-06","deletedIndicator":"No"},{"value":"PR","valueDescription":"Global Partial Response in Blood","ValueMeaning":{"publicId":"6741230","version":"1","preferredName":"Global Partial Response in Blood","longName":"6741230","preferredDefinition":"Greater than 50 percent decrease in quantitative measurements of blood tumor burden in baseline from those with high tumor burden at baseline (B2).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Global Partial Response in Blood","conceptCode":"C159971","definition":"Greater than 50 percent decrease in quantitative measurements of blood tumor burden in baseline from those with high tumor burden at baseline (B2).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"883A28B7-4575-21A5-E053-F662850ACC0A","latestVersionIndicator":"Yes","beginDate":"2019-05-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-05-06","modifiedBy":"ONEDATA","dateModified":"2019-05-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"883A28B7-458E-21A5-E053-F662850ACC0A","beginDate":"2019-05-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-05-06","modifiedBy":"ONEDATA","dateModified":"2019-05-06","deletedIndicator":"No"},{"value":"Relapse","valueDescription":"Global Relapse in Blood","ValueMeaning":{"publicId":"6741231","version":"1","preferredName":"Global Relapse in Blood","longName":"6741231","preferredDefinition":"Increase of neoplastic blood lymphocytes to B1 or greater in those with complete response.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Global Relapse in Blood","conceptCode":"C159976","definition":"Increase of neoplastic blood lymphocytes to B1 or greater in those with complete response.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"883A28B7-459A-21A5-E053-F662850ACC0A","latestVersionIndicator":"Yes","beginDate":"2019-05-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-05-06","modifiedBy":"ONEDATA","dateModified":"2019-05-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"883A28B7-45B3-21A5-E053-F662850ACC0A","beginDate":"2019-05-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-05-06","modifiedBy":"ONEDATA","dateModified":"2019-05-06","deletedIndicator":"No"},{"value":"SD","valueDescription":"Global Stable Disease in Blood","ValueMeaning":{"publicId":"6741232","version":"1","preferredName":"Global Stable Disease in Blood","longName":"6741232","preferredDefinition":"Fails to attain the criteria for complete response, partial response, or progressive disease.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Global Stable Disease in Blood","conceptCode":"C159974","definition":"Fails to attain the criteria for complete response, partial response, or progressive disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"883A28B7-45BF-21A5-E053-F662850ACC0A","latestVersionIndicator":"Yes","beginDate":"2019-05-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-05-06","modifiedBy":"ONEDATA","dateModified":"2019-05-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"883A28B7-45D8-21A5-E053-F662850ACC0A","beginDate":"2019-05-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-05-06","modifiedBy":"ONEDATA","dateModified":"2019-05-06","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"6741226","version":"1","preferredName":"Global Response in Blood Category","preferredDefinition":"Criteria for the response to treatment in blood, as a component of global response.:A grouping of items based on some commonality or by user defined characteristics.","longName":"C159969:C25372","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Global Response in Blood","conceptCode":"C159969","definition":"Criteria for the response to treatment in blood, as a component of global response.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Category","conceptCode":"C25372","definition":"A grouping of items based on some commonality or by user defined characteristics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"883A28B7-4502-21A5-E053-F662850ACC0A","latestVersionIndicator":"Yes","beginDate":"2019-05-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-05-06","modifiedBy":"ONEDATA","dateModified":"2019-05-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CCR:Center for Cancer Research","workflowStatus":"RELEASED","registrationStatus":"Application","id":"883A28B7-4513-21A5-E053-F662850ACC0A","latestVersionIndicator":"Yes","beginDate":"2019-05-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-05-06","modifiedBy":"COOPERM","dateModified":"2019-05-07","changeDescription":"Created for NCI-INC0370865: 19C0076 qns curation request 4.17.19 mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008601","version":"1","longName":"C3D Domain","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811685","version":"1","longName":"CCR","context":"CCR"}]},{"publicId":"2182125","version":"1","longName":"CCR Implementation","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811673","version":"1","longName":"C3D","context":"CCR"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Response in Blood","type":"Preferred Question Text","description":"Response in Blood","url":null,"context":"CCR"}],"origin":"CCR:Center for Cancer Research","workflowStatus":"RELEASED","registrationStatus":"Application","id":"883A7DC3-489B-2C52-E053-F662850A0E22","latestVersionIndicator":"Yes","beginDate":"2019-05-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-05-06","modifiedBy":"COOPERM","dateModified":"2019-05-08","changeDescription":"Created for NCI-INC0370865: 19C0076 qns curation request 4.17.19 mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}